

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/773,406	02/09/2004	David J. Burke	034008-003	6608	
21839	7590 03/02/2006		EXAMINER		
	AN INGERSOLL PC	KIM, YUNSOO			
•	NG BURNS, DOANE, SWI CE BOX 1404	ART UNIT	PAPER NUMBER		
	RIA, VA 22313-1404		1644		
			DATE MAILED: 03/02/2006	<b>.</b>	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summer		Appli	cation No.	on No. Applicant(s)					
		10/77	73,406	BURKE ET AL.	BURKE ET AL.				
Office Action Summary			iner	Art Unit					
			oo Kim	1644					
Period fo	The MAILING DATE of this communic or Reply	ation appears or	n the cover sheet w	vith the correspondence a	ddress				
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FO CHEVER IS LONGER, FROM THE MAnsions of time may be available under the provisions of SIX (6) MONTHS from the mailing date of this community of the properties of the provision of the period for reply is specified above, the maximum stature to reply within the set or extended period for reply we reply received by the Office later than three months after the patent term adjustment. See 37 CFR 1.704(b).	ILING DATE OF 37 CFR 1.136(a). In ranication. Itory period will apply a ill, by statute, cause the	THIS COMMUN no event, however, may a and will expire SIX (6) MO e application to become A	ICATION. reply be timely filed  NTHS from the mailing date of this. BANDONED (35 U.S.C. § 133).					
Status									
1)	Responsive to communication(s) filed	on .							
3)									
.—	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.								
Disposit	on of Claims								
4)🖂	4)⊠ Claim(s) <u>1-42</u> is/are pending in the application.								
	4a) Of the above claim(s) is/are withdrawn from consideration.								
5)	5) Claim(s) is/are allowed.								
6)	Claim(s) is/are rejected.								
7)	7) Claim(s) is/are objected to.								
8)⊠	8)⊠ Claim(s) <u>1-42</u> are subject to restriction and/or election requirement.								
Applicat	ion Papers								
9)	The specification is objected to by the	Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.									
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).									
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).									
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.									
Priority (	ınder 35 U.S.C. § 119								
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:									
	1. Certified copies of the priority documents have been received.								
	2. Certified copies of the priority documents have been received in Application No								
	3. Copies of the certified copies of the priority documents have been received in this National Stage								
	application from the Internation	al Bureau (PCT	Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.									
Attachmen	• •								
	ce of References Cited (PTO-892)	0.048)		4) Interview Summary (PTO-413) Paper No(s)/Mail Date					
3) 🔲 Infor	ce of Draftsperson's Patent Drawing Review (PT mation Disclosure Statement(s) (PTO-1449 or P er No(s)/Mail Date			Informal Patent Application (P)	mal Patent Application (PTO-152)				

Application/Control Number: 10/773,406 Page 2

Art Unit: 1644

## **DETAILED ACTION**

1. Claims 1-42 are pending.

2. Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-26, 29-32 and 41 drawn to a stable antibody formulation classified in class 424, subclass 133.1.
- II. Claims 27, 28 and 42 drawn to a method of treating classified in class 514, subclass 8.
- III. Claims 33-40 drawn to a method for preparing antibody formulation classified in class 424, subclass 130.1.

The inventions are distinct, each from the other because of the following reasons:

- 3. Groups I and II are related as product and process of using. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). The antibody that binds to alpha-4 integrin can be used in materially different processes, such as *in vitro* assays.
- 4. Groups II and III are different methods. These inventions are different with respect to ingredients, method steps, and endpoints, which require non-coextensive searches; therefore, each method is patentably distinct.
- 5. Because these inventions are independent or distinct for the reasons given above and have acquired a separate status in the art in view of their different classification, restriction for examination purposes as indicated is proper.
- 6. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Page 3

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

- 7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).
- 8. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312. In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996).

Application/Control Number: 10/773,406 Page 4

Art Unit: 1644

Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder.

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yunsoo Kim whose telephone number is 571-272-3176. The examiner can normally be reached on Monday thru Friday 8:30 - 5:00PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571-272-0841. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Yunsoo Kim

Patent Examiner

Technology Center 1600

February 22, 2006

atrick J. Nolan, Ph.D.

**Primary Examiner** 

Technology Center 1600